Table of Contents
Volume 100, Issue 7: July 2015

Cover Figure
Artistic illustration of aspects of ‘innovation in hematology’ - the new theme of the year of the European Hematology Association. (image created by www.somersault1824.com)

Editorials
849 The search for the origin of factor VIII synthesis and its impact on therapeutic strategies for hemophilia A
Valder R. Arruda
850 Dangerous liaisons: cooperation between Pbx3, Meis1 and Hoxa9 in leukemia
Ross M. W. Thorne and Thomas A. Milne
853 Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?
Matthew A. Lunning and James O. Armitage
855 Personalized medicine in adult acute lymphoblastic leukemia
Dieter Hoelzer

Review Article
859 Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT
Salyka Sengsayadeth, et al.

Articles
Red Cell Biology & Its Disorders
870 Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease
Brian T. Kalish, et al.

Coagulation & Its Disorders
881 Extrahepatic sources of factor VIII potentially contribute to the coagulation cascade correcting the bleeding phenotype of mice with hemophilia A
Diego Zanolini, et al.

Myeloproliferative Disorders
893 Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations
Carla Al Assaf, et al.

Chronic Myeloid Leukemia
898 A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
Gautam Borthakur, et al.
A cute Myeloid Leukemia

905  Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia
Maria-Paz García-Cuellar, et al.

914  Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice
Erwin M. Lee, et al.

927  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
Marina Konopleva, et al.

Acute Lymphoblastic Leukemia

935  Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia
Leonid Karawajew, et al.

Chronic Lymphocytic Leukemia

945  Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B
Manoj K. Kashyap, et al.

Non-Hodgkin Lymphoma

955  Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial
Ulrich Jaeger, et al.

Plasma Cell Disorders

964  Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MMS trial
Maximilian Merz, et al.

Stem Cell Transplantation

970  Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease
Joseph Pidala, et al.

Immunodeficiencies

978  The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis
Sebastian FN Bode, et al.

Letters to the Editor

Letters are available online only at www.haematologica.org/content/100/7.toc

e250  Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia
Harinder Gill, et al.
http://www.haematologica.org/content/100/7/e250

e254  Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia
Daisuke Araki, et al.
http://www.haematologica.org/content/100/7/e254

e257  CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis
Sara Trabanelli, et al.
http://www.haematologica.org/content/100/7/e257
e261 Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates
Judith M. Boer, et al.
http://www.haematologica.org/content/100/7/e261

e265 Higher levels of reactive oxygen species are associated with anergy in chronic lymphocytic leukemia
Adam Linley, et al.
http://www.haematologica.org/content/100/7/e265

e269 Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma
Anne-Sophie Michallet, et al.
http://www.haematologica.org/content/100/7/e269

e272 Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
Yasuhiro Oki, et al.
http://www.haematologica.org/content/100/7/e272

e275 Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern
Julio Finalet Ferreiro, et al.
http://www.haematologica.org/content/100/7/e275

e280 Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis
Elodie Bohers, et al.
http://www.haematologica.org/content/100/7/e280

e285 Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma
Michael Hahn, et al.
http://www.haematologica.org/content/100/7/e285

e289 Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma
Enrique M. Ocio, et al.
http://www.haematologica.org/content/100/7/e289